Doug Wilson was a New Zealand physician and academic. He joined a major International pharmaceutical company, Boehringer Ingelheim, working in their US subsidiary, becoming their Head of Medical Research and Regulatory Affairs, the interface with FDA, playing a major role in steering 10 drugs through the FDA to the US and global markets. He moved to Head Office in Germany, being responsible for those same functions for worldwide drug development. He chaired the company’s International Medical Committee overseeing the medical aspects of all drugs in development globally, and their Internal Labeling Committee for the drugs on the worldwide market. He was the medical parent of Spiriva, a drug for Chronic Obstructive Pulmonary Disease (COPD) one of the major global killers. The drug last year sold $5 billion. He now consults internationally on new drugs in development, and for pharmaceutical companies.